Thu.Jul 11, 2024

article thumbnail

Pfizer thinks it found its obesity pill

Bio Pharma Dive

Far behind companies like Novo and Eli Lilly, Pfizer hopes the version of the drug, danuglipron, that it’s chosen to advance can break into the ultra-lucrative market for weight-loss medicines.

Medicine 320
article thumbnail

Scientists May Have Figured Out How to Make Fat Cells Burn Calories

AuroBlog - Aurous Healthcare Clinical Trials blog

White could be the new beige when it comes to fat cells, following the discovery of a switch that maintains the functions of adipose tissue in mice, transforming it from a lipid-locker into a calorie-burner.

Scientist 246
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA’s lab-developed test rule could be first test of agency’s power post-Chevron

Bio Pharma Dive

The Supreme Court’s decision to overturn the Chevron doctrine would make it easier to challenge agency regulations, such as the LDT final rule.

article thumbnail

CDSCO issues guidance document on export NOC for unapproved, banned and new drugs

AuroBlog - Aurous Healthcare Clinical Trials blog

The Central Drugs Standard Control Organisation (CDSCO) has released guidance for the companies to attain export No Objection Certificate (NOC) for manufacture of unapproved, banned or new drugs, a process which was centralised recently.

Drugs 245
article thumbnail

Bridging Innovation & Patient Care: The Growing Role of AI

Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

article thumbnail

Novo’s once-weekly insulin rejected by FDA

Bio Pharma Dive

The FDA’s decision to turn back the drugmaker’s new insulin product narrows Novo’s lead in the U.S. over Eli Lilly, which has a similar diabetes treatment in late-stage testing.

Insulin 187
article thumbnail

Researchers awarded £1.5m for national dementia inequalities network

Pharma Times

The ESRC EquaDem Network Plus aims to improve disparities in diagnosis and care

Research 148

More Trending

article thumbnail

New policy review reveals ten cancer challenges facing new UK government

Pharma Times

Macmillan Cancer Support estimates that cancer affects over three million people in the UK

146
146
article thumbnail

Rgenta Therapeutics’ RGT-61159 gains IND approval to treat cancers

Pharmaceutical Technology

Rgenta has secured approval for its IND application for RGT-61159, an oral small molecule RNA modulator, to treat cancers.

RNA 147
article thumbnail

FTC said to be planning legal action against PBMs

pharmaphorum

The FTC is said to be gearing up to file lawsuits against the top three pharmacy benefit managers in the wake of its damning report on the sector.

Pharmacy 124
article thumbnail

J&J asserts its place in atopic dermatitis space with Yellow Jersey acquisition

Pharmaceutical Technology

J&J gains Phase II ready NM26, a bispecific antibody in development for the treatment of atopic dermatitis.

Antibody 130
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Bill that would cut down ‘patent thickets’ clears Senate

pharmaphorum

The US Senate has come together to pass a bill that aims to prevent pharma companies from filing multiple patents around biologic drugs as a way to delay biosimilar competitors.Lawmakers unanimously passed the Affordable Prescriptions for Patients Act of 2023 (S-150), which is part of a lengthening list of measures being taken by Congress to curb the prices of medicines in the US.

article thumbnail

Boehringer Ingelheim plans sustainability work for the long term

Pharmaceutical Technology

Boehringer Ingelheim’s For Generations framework is all in on sustainability for the long term across the ESG spectrum.

130
130
article thumbnail

SK Life Science Leverages Smart, Efficient Solutions Across its Engaged Industry-Leading Sales Team

pharmaphorum

SK Life Science Leverages Smart, Efficient Solutions Across its Engaged Industry-Leading Sales Team Mike.

article thumbnail

After AdCom rejection, FDA rebuffs Novo Nordisk’s once-weekly insulin

Pharmaceutical Technology

The company did not expect to resolve concerns related to manufacturing and the safety profile for type 1 diabetes by the end of the year.

Insulin 130
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Senate unanimously endorses legislation targeting pharma 'patent thickets'

Fierce Pharma

Even as pharma companies have yet to feel the full effects of the Inflation Reduction Act, Senate lawmakers have turned their attention to another facet of drug pricing with a bill meant to cr | The bill looks to limit the number of patents that companies can assert in litigation on individual products. It's intended to crack down on "patent thickets," which can delay and thwart generic competition.

article thumbnail

Aspect wins $72.75m from Canadian government for bioprinted pipeline

Pharmaceutical Technology

Novo Nordisk-partnered Aspect develops bioprinted tissue therapeutics designed to replace or support specific biological functions.

article thumbnail

How is the rise of GenAI changing the field of pharma medical writing?

pharmaphorum

The rise of GenAI is revolutionising the field of pharma medical writing in biopharma. Explore how this innovative technology is transforming the industry and its impact on medical writing practices.

117
117
article thumbnail

Merz wins $185m bid for bankrupt Acorda assets and increases US workforce by 50%

Pharmaceutical Technology

The deal strengthens Merz’s market position in Parkinson’s disease whilst expanding into the multiple sclerosis sector.

Marketing 130
article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

Clinical trial trends and the rise of site networks

pharmaphorum

Tune in to Caroline Redecker and Jason Casarella as they discuss clinical trial trends and the rise of site networks in this insightful podcast episode brought to you by Advanced Clinical.

article thumbnail

Biotech survey highlights where industry can focus for a thriving future  

Pharmaceutical Technology

Research suggests biomanufacturing specialists remain nervy about global supply chain resilience.

Research 130
article thumbnail

How to get into a clinical trial? Understanding inclusion and exclusion criteria

Antidote

When determining which clinical trial is the right fit , many factors must be considered. The site location, the number of required visits, and the length of the study are all important considerations, but before any of this, it is vital to consider the study's inclusion and exclusion criteria.

article thumbnail

AusperBio AHB-137 gains breakthrough status in China for CHB  

Pharmaceutical Technology

AusperBio Therapeutics and Ausper Biopharma have received breakthrough therapy designation in China for AHB-137 for CHB.

130
130
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

The end of the beginning: Lilly execs eye top spot in burgeoning Alzheimer's market after Kisunla's FDA approval

Fierce Pharma

Following this month's FDA approval of Eli Lilly’s amyloid-busting antibody Kisunla (donanemab), the Alzheimer’s disease market is set to grow in earnest—and Lilly is already eyeing a spot at the t | On top of Eisai and Biogen's Leqembi, Kisunla’s approval likely marks the “end of the beginning in treating this disease,” Andrew Lechleiter, VP of U.S.

article thumbnail

Hong Kong approves Leqembi for Alzheimer’s treatment

Pharmaceutical Technology

BioArctic has announced that its partner, Eisai has approval from Hong Kong's Department of Health for Leqembi for the treatment of AD.

130
130
article thumbnail

FDA rejects Novo Nordisk’s weekly basal insulin

pharmaphorum

FDA rejects Novo Nordisk’s once-weekly basal insulin for people with diabetes, which would reduce the number of injections needed

Insulin 111
article thumbnail

CDMO Value Proposition: Why It Matters

Drug Patent Watch

The value proposition of Contract Development and Manufacturing Organizations (CDMOs) has become increasingly crucial in the pharmaceutical industry.

article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

article thumbnail

AbbVie lines up Thakkar to replace outgoing CSO Hudson

pharmaphorum

Change of R&D chiefs at AbbVie, as Thomas Hudson steps down as CSO and is replaced by Roopal Thakkar.

109
109
article thumbnail

Meet Ketaki Patwardhan - from experiements with dad to excipients and manufacturing at Roquette

Outsourcing Pharma

Ketaki Patwardhan, a global technical developer at Roquette, has built a remarkable career in the pharmaceutical industry by leveraging her curiosity and passion for science.

article thumbnail

Electrolyte Beverages: Trends and Innovations in 2024

XTalks

The electrolyte beverage market is rapidly growing in 2024, driven by consumer demand for functional drinks. Electrolytes are minerals like sodium, potassium and magnesium that are essential for various bodily functions, including hydration, muscle function and nerve signaling. As more people recognize the benefits of these nutrients, the popularity of electrolyte beverages has surged.

Branding 105
article thumbnail

Pharma Pulse 7/11/24: Thermo Fisher Scientific Completes Acquisition of Olink, 7 Takeaways From the FTC Interim Report on PBMs & more

Pharmaceutical Commerce

The latest news for pharma industry insiders.

105
105
article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud